^
    13d
    HER2 status results in an unstable switch from primary to recurrent breast cancer. (PubMed, Neoplasma)
    HER2 expression in primary and recurrent breast cancer samples was highly unstable. Discordance was more frequently observed in the HR-positive population.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
    15d
    Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy. (PubMed, Am J Cancer Res)
    HER-2 zero to low conversion was associated with better DFS in patients who are HER-2 zero. These results provide a valuable reference for the potential application of anti-HER-2 ADC in an adjuvant setting for patients with residual disease after NAC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR negative • HER-2 amplification + HR-positive • HER-2 negative + HR negative
    3ms
    Hormone receptor-positive early-stage breast carcinomas are enriched in HER2-low phenotype and low levels of tumour-infiltrating lymphocytes (ECP 2024)
    Early-stage HR-positive breast carcinomas have low TIL levels regardless of the recurrence risk, molecular subtype, and HER2- low status. These cancers are markedly enriched by HER2-low phenotype, which might have therapeutic implications due to the recently approved anti-HER2 antibody-drug conjugate.
    Tumor-infiltrating lymphocyte
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 amplification + HR-positive
    |
    MammaPrint • BluePrint